IRIDEX to Report Second Quarter 2020 Financial Results on August 6, 2020
IRIDEX Corporation (Nasdaq: IRIX) will announce its second quarter 2020 financial results after trading on August 6, 2020.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
IRIDEX Corporation (Nasdaq: IRIX) will announce its second quarter 2020 financial results after trading on August 6, 2020. Management will host a conference call at 2:00 p.m. PT / 5:00 p.m. ET, with dial-in options for domestic (844-707-0665) and international callers (703-326-3030), using conference ID: 6486158. A live and archived webcast will be available on the company’s website. IRIDEX specializes in laser-based medical systems for ophthalmology, utilizing its MicroPulse® technology to address conditions like glaucoma and diabetic macular edema.
Details
News Market Reaction – IRIX
The recorded move for IRIX in the trading session of this news was +2.20%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
MOUNTAIN VIEW, Calif., July 23, 2020 (GLOBE NEWSWIRE) -- IRIDEX Corporation (Nasdaq: IRIX) today announced the Company will release financial results for the second quarter of 2020 after the close of trading on Thursday, August 6, 2020. The Company’s management team will host a corresponding conference call beginning at 2:00 p.m. PT / 5:00 p.m. ET.
Investors interested in listening to the conference call may do so by dialing (844) 707-0665 for domestic callers or (703) 326-3030 for international callers, using conference ID: 6486158. A live and archived webcast of the event will be available on the “Investors” section of the Company’s website at: www.iridex.com.
About IRIDEX
IRIDEX Corporation is a worldwide leader in developing, manufacturing, and marketing innovative and versatile laser-based medical systems, delivery devices and consumable instrumentation for the ophthalmology market. The Company’s proprietary MicroPulse® technology delivers a differentiated treatment that provides safe, effective, and proven treatment for targeted sight-threatening eye conditions. IRIDEX’s current product line is used for the treatment of glaucoma and diabetic macular edema (DME) and other retinal diseases. IRIDEX products are sold in the United States through a direct sales force and internationally primarily through a network of independent distributors into more than 100 countries. For further information, visit the IRIDEX website at www.iridex.com.
Investor Relations Contact:
Leigh Salvo
(415) 937-5404
investors@iridex.com
Media Contact:
Jamie Hall
Pascale Communications, LLC.
(724) 417-0167
pr@iridex.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.